Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

Amgen and Eli Lilly unveiled new data for their experimental heart drugs that target lipoprotein(a) — a cholesterol carrier that can increase the risk of heart diseases — as the industry races to develop the next big class of cardio drugs.

Olpasiran’s long-lasting effect

Amgen Click here to view original post